Company intelligence / Profile preview

Strategic Science & Technologies-D

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~13
Development stage: Other

Overview

SST’s lead program SST-6007, a topical sildenafil cream for Female Sexual Arousal Disorder (FSAD), has advanced to Phase 2 with positive Phase 1 results indicating safety and tolerability. SST-6006, a similar topical for male erectile dysfunction, completed Phase 1 with promising safety and pharmacokinetic data. Both programs utilize the company's KNOSIS topical delivery technology.

Therapeutic areas: RheumatologyWomen's HealthInfectious DiseasesNeurologyMen's Health
Modalities: Small molecule
Industry: Biotech

Partnerships

Daré Bioscience

Beyond the preview

Go deeper on Strategic Science & Technologies-D.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Strategic Science & Technologies-D.

Explore the full profile